FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2077534178> ?p ?o ?g. }

• W2077534178 endingPage "15" @default.
• W2077534178 startingPage "13" @default.
• W2077534178 abstract "Yildirim Beyazit University, Faculty of Medicine, Department of Medical Oncology, 06800, Ankara, Turkey Hacettepe University Cancer Institute, Department of Medical Oncology, Ankara, Turkey *Author for correspondence: Tel.: +90 312 2912525; masendur@yahoo.com.tr Trastuzumab is the first humanized monoclonal antibody that binds to the extracellular domain of HER2 [1,2]. Adding trastuzumab to standard chemotherapy significantly improves response rates, progression-free survival and overall survival in patients with HER2-positive metastatic breast cancer (MBC) [3,4]. Although trastuzumab is the major cornerstone of the treatment of HER2-positive MBC, the majority of patients with MBC who initially respond to trastuzumab demonstrate disease progression within 1 year of trastuzumab treatment [3]. The lack of response to trastuzumab of HER2positive MBC in some patients challenges clinicians to find new therapies directed at HER2. Pertuzumab, a new recombinant humanized monoclonal antibody, prevents the dimerization of HER2 with other HER receptors (HER3, HER1 and HER4), especially with HER3, by binding to the HER2 dimerization domain [5]. The randomized, double-blind, placebo-controlled, Phase III CLEOPATRA study showed that adding pertuzumab to a trastuzumab plus docetaxel combination was associated with significantly improved progression-free survival and overall survival in patients with treatmentnaive HER2-positive MBC [6,7]. Both of the randomized NEOSPHERE and TRYPHAENA trials showed significantly improved pathological complete response rates when adding pertuzumab to trastuzumab arms compared with trastuzumab-alone arms in the neoadjuvant setting [8,9]. Due to the combination of dual antibodies against HER2 being more active compared with single anti-HER2 treatment, the US FDA approved pertuzumab in combination with trastuzumab in the neoadjuvant setting and in treatment-naive MBC. Trastuzumab-induced cardiotoxicity (TIC) is the main dose-limiting adverse event in HER2positive breast cancer patients treated with trastuzumab [10]. In a pivotal trial, the risks of TIC were 27 and 13% in patients treated with anthracycline plus cyclophosphamide with trastuzumab concomitantly and trastuzumab plus paclitaxel, respectively [10]. In a meta-analyses of ten randomized controlled trials, the incidence of TIC was reported to be 7.5%, with a 1.9% incidence of congestive heart failure among 11,882 patients receiving trastuzumab [11]. The combination of pertuzumab with trastuzumab demonstrated signif icant tumor regression compared with trastuzumab or pertuzumab alone in xenograft tumor model" @default.
• W2077534178 created "2016-06-24" @default.
• W2077534178 creator A5027860268 @default.
• W2077534178 creator A5052748672 @default.
• W2077534178 creator A5090532877 @default.
• W2077534178 date "2015-01-01" @default.
• W2077534178 modified "2023-10-16" @default.
• W2077534178 title "Pertuzumab-induced cardiotoxicity: safety compared with trastuzumab" @default.
• W2077534178 cites W1976148354 @default.
• W2077534178 cites W1982210988 @default.
• W2077534178 cites W2001298924 @default.
• W2077534178 cites W2011952494 @default.
• W2077534178 cites W2035642783 @default.
• W2077534178 cites W2050060618 @default.
• W2077534178 cites W2083486298 @default.
• W2077534178 cites W2089071484 @default.
• W2077534178 cites W2095861620 @default.
• W2077534178 cites W2096111541 @default.
• W2077534178 cites W2101299592 @default.
• W2077534178 cites W2104239861 @default.
• W2077534178 cites W2107427447 @default.
• W2077534178 cites W2120661754 @default.
• W2077534178 cites W2123591186 @default.
• W2077534178 cites W2149773268 @default.
• W2077534178 cites W2151425644 @default.
• W2077534178 cites W2166199281 @default.
• W2077534178 cites W2318605753 @default.
• W2077534178 cites W4239462698 @default.
• W2077534178 cites W4248045393 @default.
• W2077534178 doi "https://doi.org/10.2217/fon.14.184" @default.
• W2077534178 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25572781" @default.
• W2077534178 hasPublicationYear "2015" @default.
• W2077534178 type Work @default.
• W2077534178 sameAs 2077534178 @default.
• W2077534178 citedByCount "11" @default.
• W2077534178 countsByYear W20775341782016 @default.
• W2077534178 countsByYear W20775341782017 @default.
• W2077534178 countsByYear W20775341782019 @default.
• W2077534178 countsByYear W20775341782020 @default.
• W2077534178 countsByYear W20775341782021 @default.
• W2077534178 countsByYear W20775341782023 @default.
• W2077534178 crossrefType "journal-article" @default.
• W2077534178 hasAuthorship W2077534178A5027860268 @default.
• W2077534178 hasAuthorship W2077534178A5052748672 @default.
• W2077534178 hasAuthorship W2077534178A5090532877 @default.
• W2077534178 hasConcept C121608353 @default.
• W2077534178 hasConcept C126322002 @default.
• W2077534178 hasConcept C143998085 @default.
• W2077534178 hasConcept C2778233292 @default.
• W2077534178 hasConcept C2779786085 @default.
• W2077534178 hasConcept C2781164504 @default.
• W2077534178 hasConcept C29730261 @default.
• W2077534178 hasConcept C530470458 @default.
• W2077534178 hasConcept C71924100 @default.
• W2077534178 hasConcept C98274493 @default.
• W2077534178 hasConceptScore W2077534178C121608353 @default.
• W2077534178 hasConceptScore W2077534178C126322002 @default.
• W2077534178 hasConceptScore W2077534178C143998085 @default.
• W2077534178 hasConceptScore W2077534178C2778233292 @default.
• W2077534178 hasConceptScore W2077534178C2779786085 @default.
• W2077534178 hasConceptScore W2077534178C2781164504 @default.
• W2077534178 hasConceptScore W2077534178C29730261 @default.
• W2077534178 hasConceptScore W2077534178C530470458 @default.
• W2077534178 hasConceptScore W2077534178C71924100 @default.
• W2077534178 hasConceptScore W2077534178C98274493 @default.
• W2077534178 hasIssue "1" @default.
• W2077534178 hasLocation W20775341781 @default.
• W2077534178 hasLocation W20775341782 @default.
• W2077534178 hasOpenAccess W2077534178 @default.
• W2077534178 hasPrimaryLocation W20775341781 @default.
• W2077534178 hasRelatedWork W2016884538 @default.
• W2077534178 hasRelatedWork W2077534178 @default.
• W2077534178 hasRelatedWork W2083486298 @default.
• W2077534178 hasRelatedWork W2800519327 @default.
• W2077534178 hasRelatedWork W2994937700 @default.
• W2077534178 hasRelatedWork W3085471239 @default.
• W2077534178 hasRelatedWork W3139229505 @default.
• W2077534178 hasRelatedWork W4206213581 @default.
• W2077534178 hasRelatedWork W4214767076 @default.
• W2077534178 hasRelatedWork W4253290180 @default.
• W2077534178 hasVolume "11" @default.
• W2077534178 isParatext "false" @default.
• W2077534178 isRetracted "false" @default.
• W2077534178 magId "2077534178" @default.
• W2077534178 workType "article" @default.